Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Algernon Pharmaceuticals Inc (AGNPF)

Algernon Pharmaceuticals Inc (AGNPF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade AGNPF with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1045 +6.41%
on 06/18/21
0.1412 -21.25%
on 06/04/21
-0.0214 (-16.14%)
since 05/18/21
3-Month
0.1045 +6.41%
on 06/18/21
0.3032 -63.32%
on 03/23/21
-0.1689 (-60.30%)
since 03/18/21
52-Week
0.1045 +6.41%
on 06/18/21
0.4385 -74.64%
on 12/15/20
-0.0418 (-27.32%)
since 06/18/20

Most Recent Stories

More News
Algernon Pharmaceuticals Targets First Human Study of its Psychedelic Drug DMT Stroke Program for Q4, 2021

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the "Company" or "Algernon") is pleased to announce that all of the required permits and licenses for the manufacture of its cGMP...

AGN.CN : 0.135 (-6.90%)
AGNPF : 0.1112 (-5.76%)
Algernon Pharmaceuticals Launches Pancreatic Cancer Clinical Research Program with Ifenprodil

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the "Company" or "Algernon") announces it has initiated a new clinical research program for pancreatic cancer (PC) and NP-120 (Ifenprodil)....

AGN.CN : 0.135 (-6.90%)
AGNPF : 0.1112 (-5.76%)
Algernon Pharmaceuticals Highlights New Animal Study Showing Effectiveness of Psychedelic Drug DMT in Treatment of Stroke

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the "Company" or "Algernon") is pleased to highlight an independent research study from the University of Szeged in Hungary describing...

AGN.CN : 0.135 (-6.90%)
AGNPF : 0.1112 (-5.76%)
Algernon Pharmaceuticals Receives Positive Feedback from U.S. FDA for Psychedelic Drug DMT Clinical Research Program for Stroke

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the "Company" or "Algernon") announces it has received positive feedback from the U.S. Food and Drug Administration (FDA) regarding...

AGN.CN : 0.135 (-6.90%)
AGNPF : 0.1112 (-5.76%)
Algernon Pharmaceuticals Announces Ifenprodil Reduced Interleukin 6 in Phase 2b/3 COVID Study

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the "Company" or "Algernon") a clinical stage pharmaceutical development company announces that NP-120 (Ifenprodil) reduced interleukin...

AGNPF : 0.1112 (-5.76%)
AGN.CN : 0.135 (-6.90%)
BTHCF : 0.0363 (-11.46%)
Algernon Pharmaceuticals Announces 50% Enrollment of its Ifenprodil IPF and Chronic Cough Phase 2 Human Study

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the "Company" or "Algernon") a clinical stage pharmaceutical development company is pleased to announce that it has reached 50%...

AGNPF : 0.1112 (-5.76%)
AGN.CN : 0.135 (-6.90%)
BTHCF : 0.0363 (-11.46%)
Algernon Pharmaceuticals Files End of Phase 2 Meeting Request with U.S. FDA for its COVID-19 Trial of Ifenprodil

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the "Company" or "Algernon") a clinical stage pharmaceutical development company, announces that it has filed an end of Phase 2...

AGN.CN : 0.135 (-6.90%)
AGNPF : 0.1112 (-5.76%)
Algernon Pharmaceuticals to File End-of-Phase 2 Meeting Request with U.S. FDA for Possible Ifenprodil Phase 3 COVID-19 Trial

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the "Company" or "Algernon") a clinical stage pharmaceutical development company, is pleased to announce that it plans to formalize...

AGN.CN : 0.135 (-6.90%)
AGNPF : 0.1112 (-5.76%)
Algernon Pharmaceuticals Announces Appointment of Global Expert Dr. Steven L. Wolf for DMT Stroke Program

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the "Company" or "Algernon") a clinical stage pharmaceutical development company, is pleased to announce that it has appointed...

AGN.CN : 0.135 (-6.90%)
AGNPF : 0.1112 (-5.76%)
Algernon Pharmaceuticals Announces Topline Data From its Phase 2b/3 COVID-19 Trial of Ifenprodil

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the "Company" or "Algernon") a clinical stage pharmaceutical development company, is pleased to announce topline data from the...

AGN.CN : 0.135 (-6.90%)
AGNPF : 0.1112 (-5.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Key Turning Points

3rd Resistance Point 0.1280
2nd Resistance Point 0.1219
1st Resistance Point 0.1166
Last Price 0.1112
1st Support Level 0.1052
2nd Support Level 0.0991
3rd Support Level 0.0938

See More

52-Week High 0.4385
Fibonacci 61.8% 0.3109
Fibonacci 50% 0.2715
Fibonacci 38.2% 0.2321
Last Price 0.1112
52-Week Low 0.1045

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar